Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The design and synthesis of highly efficient FAK inhibitor for the potential treatment of colorectal cancer harboring KRAS mutation.

Bioorganic chemistry - 15 Sept 2026

Zheng Xu, Wang Yiru, Qiao Yanlong, Chen Zhiping, Khezrirad Fatemeh, Han Qingxuan, Li Lei, Yuan Bo, Cui Hongxia, Chen Lixue

Abstract excerpt

Herein, a series of 2-arylaminopyrimidine derivatives were designed and synthesized as new type of Focal adhesion kinase (FAK) inhibitors. Among them, 7g, as a promising compound, demonstrated a strong combining capability to FAK with a half-maximal inhibitory concentration (IC50) of 10.87 nM, and displayed effective antiproliferative activities against colorectal cells HCT116 (IC50 = 0.460 μM) in vitro. The...

Topics

Join the communities discussing this publication.

Drug Design
Drug Screening Assays, Antitumor
Focal Adhesion Kinase 1
Focal Adhesion Protein-Tyrosine Kinases
Mice, Nude

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Molecular Structure

Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 42379010
DOI: 10.1016/j.bioorg.2026.110171

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The design and synthesis of highly efficient FAK inhibitor for the potential treatment of colorectal cancer harboring KRAS mutation.PMID 42379010Read ↗

Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsSemantic proximity Read ↗

Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.Semantic proximity Read ↗

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read ↗

FAK signaling in human cancer as a target for therapeuticsSemantic proximity Read ↗

New Insights on the Nuclear Functions and Targeting of FAK in CancerSemantic proximity Read ↗

Understanding the Roles of FAK in CancerSemantic proximity Read ↗

Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial.Semantic proximity Read ↗

FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.Semantic proximity Read ↗

Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).Semantic proximity Read ↗

Focal adhesion kinase and cancer.Semantic proximity Read ↗

Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.Semantic proximity Read ↗

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.